Please wait while the formulary information is being retrieved.
LUMIZYME (ALGLUCOSIDASE ALFA)
- Lysosomal alpha-1,4-glucosidase deficiency
50 mg intravenous solution
- Infuse 20 mg/kg over 4 hour(s) by intravenous route every 2 weeks at a rate of 1 mg/kg/hr for 30 minutes may increase to a max of 7 mg/kg/hr
Lysosomal alpha-1,4-glucosidase deficiency
- Infuse 20 mg/kg over approximately 4 hour(s) by intravenous route every 2 weeks at a rate of 1 mg/kg/hr for 30 minutes may increase up to amax rate of 7 mg/kg/hr
- Infuse 20 mg/kg over 4 hour(s) by intravenous route every 2 weeks at a rate of 1 mg/kg/hr for 30 minutes may increase to a max of 7 mg/kg/hr
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Cardiopulmonary impairment
- Hypervolemia
Severe
Moderate
- None
LUMIZYME (ALGLUCOSIDASE ALFA)
- Lysosomal alpha-1,4-glucosidase deficiency
- Anaphylaxis
- Angioedema
- Bronchospastic pulmonary disease
- Cyanosis
- Hypertension
- Hypoxia
- Infection
- Tachypnea
- Urticaria
- Agitation
- Chest pain
- Cough
- Diarrhea
- Dizziness
- Erythema
- Fatigue
- Fever
- Flushing
- Headache disorder
- Hypotension
- Malaise
- Myalgias
- Nausea
- Periorbital edema
- Pharyngitis
- Rhinitis
- Skin rash
- Twitching
- Upper abdominal pain
- Vomiting
- Wheezing
More Frequent
Severe
Less Severe
- Anemia
- Apnea
- Bradycardia
- Drug fever
- Hypoventilation
- Seizure disorder
- Tachycardia
- Throat constriction
- Back pain
- Constipation
- Gastroenteritis
- Hyperhidrosis
- Pallor
- Paresthesia
- Pruritus of skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory insufficiency
- Bacterial sepsis
- Cardiac arrest
- Cerebrovascular accident
- Dermal necrosis
- Dissection of aorta
- Dyspnea
- Heart failure
- Hypersensitivity drug reaction
- Nephrotic syndrome
- Pneumonia
- Pneumothorax
- Severe dyspnea
Less Severe
- Acute abdominal pain
- Arthralgias
- Chills
- Conjunctivitis
- Muscle spasm
- Nervousness
- Pain
- Proteinuria
- Skin inflammation
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Alglucosidase alfa
Children with infantile-onset disease and underlying cardiac hypertrophy require additional monitoring. Increased risk of acute cardiorespiratory failure and risk of arrhythmia with concurrent general anesthesia.
- 1 Day – 18 Years
- Children with infantile-onset disease and underlying cardiac hypertrophy require additional monitoring. Increased risk of acute cardiorespiratory failure and risk of arrhythmia with concurrent general anesthesia.
Alglucosidase Alfa
- Severity Level:
2
- Additional Notes: Insufficient human data; some alglucosidase alfa products are fda category b
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Alglucosidase Alfa
Limited human data; short half-life in milk; infant absorption unlikely
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited human data; short half-life in milk; infant absorption unlikely |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Lysosomal alpha-1,4-glucosidase deficiency | |
| E74.02 | Pompe disease |
| 0-9 | A-Z |
|---|---|
| E74.02 | Pompe disease |
Formulary Reference Tool